Physical Address

304 North Cardinal St.
Dorchester Center, MA 02124

admin

admin

FDA Approves Lebrikizumab for Atopic Dermatitis

The US Food and Drug Administration (FDA) has approved the targeted interleukin (IL)-13 inhibitor lebrikizumab (Ebglyss) for the treatment of adults and children age 12 years and older who have moderate-to-severe atopic dermatitis (AD) that is not well controlled, despite…

en_USEnglish